Potential interactions between pangenotypic direct-acting antivirals and concomitant cardiovascular therapies in patients with chronic hepatitis C virus infection

Antoni Sicras-Mainar¹ and Ramón Morillo-Verdugo²

Abstract
Objective: To identify potential drug interactions (DIs) between pangenotypic direct-acting antivirals (pDAAs) and concomitant cardiovascular (CV) therapies in patients with chronic hepatitis C (CHC).

Methods: A retrospective observational study was carried out. Patients ≥18 years of age diagnosed with CHC and treated with pDAAs during 2017 were included. Information was collected on concomitant CV therapies and potential DIs [www.hep-druginteractions.org]. The pDAAs analyzed were sofosbuvir/velpatasvir (SOF/VEL), glecaprevir/pibrentasvir (GLE/PIB) and sofosbuvir/velpatasvir/voxilaprevir (SOF/VEL/VOX). An analysis including lipid-lowering drugs was also performed.

Results: In total, 1286 patients (mean age 64.9 years, 56.6% men) were recruited. The percentages of potential DIs with CV drugs were 1.9% contraindications, 38.1% clinically significant and 2.4% weak. When lipid-lowering drugs were included, the percentages of potential DIs with CV drugs were 10.3% contraindications, 46.3% clinically significant and 3.2% weak. Potential DIs associated with each pDAA were as follows (contraindications; clinically significant; weak): SOF/VEL (1.4%; 23.0%; 0.9%), GLE/PIB (12.8%; 60.8%; 4.7%) and SOF/VEL/VOX (16.6%; 55.1%; 4.9%).

¹Scientific Management, Health Economics and Outcomes Research, Atrys Health, Barcelona, Spain
²Pharmacist, Specialist in Hospital Pharmacy, Hospital de Valme, AGS Sur de Sevilla, Spain

Corresponding author:
Antoni Sicras Mainar, Scientific Management, Health Economics and Outcomes Research, Atrys Health, C/Provença 392, Bajos, 08025, Barcelona, Spain.
Email: ansicras@atryshealth.com
Conclusions: Approximately on third of patients with CHC are concomitantly treated with CV drugs. SOF/VEL may have fewer DIs with CV drugs than other pDAAs.

Keywords
Chronic hepatitis C, cardiovascular drugs, drug interactions, pangenotypic direct-acting antivirals, lipid-lowering drugs, retrospective study

Date received: 15 June 2020; accepted: 16 September 2020

Introduction
Chronic hepatitis C virus (HCV) infection is a worldwide public health problem with an estimated prevalence of 1% to 2% among the general population.1–4 Research into viral replication mechanisms has identified potential therapeutic targets.5 The development of new direct-acting antivirals (DAAs) against HCV was a great step forward in the treatment of this infection. The aim of these drugs is to achieve greater efficacy and safety, with fewer side effects, including potential drug interactions (DIs). Many DIs arise from drug metabolism mediated by cytochrome P450 (isoenzyme CYP3A) and/or P-glycoprotein transport.6,7

For several years, treatment regimens were used according to the HCV genotype in each individual patient. However, current DAAs are pangenotypic (pDAAs) and are effective against all HCV genotypes.8 A single DAA alone cannot prevent HCV replication and mutation. For this reason, treatment should comprise 2 to 3 drugs from different inhibitor classes.9

In general, patients receiving pDAAs are older and have increased risks of comorbidities. Thus, they may be receiving several drugs, which can result in adverse effects arising from DIs.10 In addition, DIs with therapies used to treat comorbidities may contraindicate the use of pDAAs.10–12 A recent study conducted in Spain reported high rates of comorbidities and concomitant medication rates in patients with HCV. The most commonly prescribed therapies with potential DIs were those related to the cardiovascular (CV) system and the central nervous system.13

Careful review of the medications used by patients with HCV is therefore advisable.2,10–13 Little information is currently available on the true risks of DAAs based on patterns of concomitant medication use at the population level. The objective of our study was thus to identify DIs between pDAAs and concomitant CV therapies in patients with HCV in standard clinical practice in Spain.

Patients and methods
An observational, retrospective study based on review of medical records (from electronic databases) was carried out. The study population was obtained from the records of healthcare providers corresponding to different Spanish centers (unified in the BIG-PAC anonymized database).14 Data were derived from electronic medical records and other supplementary databases from seven Spanish Autonomous Communities (1.8 million patients). Before exporting from the BIG-PAC database, all electronic records were rigorously anonymized by the centers/hospitals of origin in compliance with Organic Law 3/2018 on
the Protection of Personal Data and Guarantee of Digital Rights. Patients ≥18 years of age diagnosed with HCV infection (ICD-10-MC [B18.2]) and treated with pDAAs during 2017 were consecutively recruited. The patients were required to meet the following criteria: (i) age ≥18 years; (ii) diagnosis of HCV infection at least 12 months prior to the start of the study (patients active in the database); (iii) enrolment in the chronic medication program for obtaining medical prescriptions (with a documented record of the daily dose and duration of each treatment and ≥2 prescriptions over the follow-up period for any drug administered); and (iv) regular monitoring throughout the study (≥2 healthcare registries in the electronic system). Patients who transferred to other sites, as well as those who moved outside the study area, were excluded.

The study variables included demographic data, body mass index (BMI, kg/m²), HCV duration, personal history (detailed in Table 1) and comorbidities (ICD-10-MC). The Charlson comorbidity index was used as a summary variable of general comorbidity to assess severity. Among patients with HCV infection, we identified those receiving concomitant treatment with one of the following CV drug classes: anticoagulants, cardiac therapy, antihypertensive agents, diuretics, beta-blockers, calcium channel blockers, and agents acting on the renin–angiotensin system. Treatment description was based on the Anatomical Therapeutic Chemical Classification System. Patient assignment to a concrete treatment regimen was determined according to standard clinical practice. The pDAAs selected were sofosbuvir/velpatasvir (SOF/VEL), glecaprevir/pibrentasvir (GLE/PIB) and sofosbuvir/velpatasvir/voxilaprevir (SOF/VEL/VOX). Concomitant medications were analyzed during the antiviral treatment period, and only chronic or regular medications administered to patients were assessed. An additional analysis was performed including lipid-lowering medications. Contraindicated drugs and major interactions were described.

| Table 1. General characteristics of study patients. |
|--------------------------------------------------|
| Patients receiving CV medication n = 1286        |
| Mean age, years                                  | 64.9 (12.5) |
| Gender (male)                                    | 55.6%       |
| Mean Charlson index                              | 1.6 (1.1)   |
| Specific comorbidities                           |             |
| Arterial hypertension                            | 68.1%       |
| Diabetes mellitus                                | 29.8%       |
| Dyslipidemia                                     | 41.6%       |
| Obesity                                          | 17.6%       |
| Active smokers                                   | 11.2%       |
| Alcoholism                                       | 2.9%        |
| Ischemic heart disease                           | 11.2%       |
| Stroke                                           | 8.1%        |
| Heart failure                                    | 6.8%        |
| Renal failure                                    | 7.3%        |
| Bronchial asthma                                 | 6.3%        |
| COPD                                             | 15.4%       |
| Neuropathies                                     | 3.5%        |
| Dementia (all types)                             | 7.6%        |
| Depressive syndrome                              | 12.7%       |
| Anxiety disorder                                 | 36.5%       |
| Organic psychosis                                | 3.4%        |
| HIV/AIDS                                         | 1.7%        |
| Addictions                                       | 5.7%        |
| Osteoporosis                                     | 14.1%       |
| Cirrhosis                                        | 3.3%        |
| Other characteristics                            |             |
| Time since diagnosis, years                      | 23.5 (4.2)  |
| BMI, kg/m²                                       | 28.1 (5.3)  |
| Genotype                                         |             |
| G1a                                              | 28.2%       |
| G1b                                              | 31.2%       |
| G2                                               | 4.3%        |
| G3                                               | 14.2%       |
| G4                                               | 8.5%        |
| G5 or G6                                         | 3.5%        |
| Unknown                                          | 10.1%       |

Values reported as mean (standard deviation) or percentages. CV, cardiovascular; BMI, body mass index; COPD, chronic obstructive pulmonary disease; HIV/AIDS, human immunodeficiency virus/acquired immunodeficiency syndrome.
To identify potential DIs, the guidelines of the University of Liverpool\textsuperscript{17} were followed. This resource is recommended by the European Association for the Study of the Liver.\textsuperscript{2} Potential DIs were classified as contraindications, clinically significant, or weak. In addition, we identified the main indications for prescription of drugs such as enalapril, atorvastatin, amiodarone and digoxin.

Data were anonymized and all analyses were confidential, in accordance with Spanish legislation on personal data protection. The study was classified by the Spanish Agency for Medicines and Health Products (EPA-OD) and was subsequently approved by the Clinical Research Ethics Committee of the Unió Catalana Balears de Hospitals de Barcelona, Spain (reference: 15/49). According to Spanish legislation, retrospective studies of secondary data do not require written informed consent of the patient. Data were validated to ensure quality and consistency of the records. Descriptive univariate statistical analyses were performed. The SPSSWIN version 23 statistical package was used for all analyses. Values of $p < 0.05$ were considered statistically significant.

**Results**

We identified 1286 HCV patients (37.5%) receiving chronic CV medications (Figure 1). Table 1 shows the general characteristics of the patients. Patients were 64.9 years old on average (standard deviation [SD]: 12.5 years) and 56.6% were men. Their mean BMI was 28.1 kg/m\textsuperscript{2}, and the mean Charlson index was 1.6 (SD: 1.1). The most common comorbidities were arterial hypertension (68.1%), dyslipidemia (41.6%), anxiety disorders (36.5%) and diabetes (29.8%). The mean number of

![Figure 1. Study flow chart.](image)

HCV: chronic hepatitis C virus infection; CV: cardiovascular.
medications received was 3.6 (SD: 2.5) per patient per year.

The drugs administered for CV therapy (excluding lipid-lowering drugs) showing potential DIs with pDAAs included enalapril (n = 365), amlodipine (n = 150), acenocoumarol (n = 77), olmesartan (n = 73) and valsartan (n = 60) (Table 2). The percentages of potential DIs associated with CV drugs were 1.9% contraindications, 38.1% clinically significant and 2.4% weak. The percentages of DIs associated with each class of pDAAs were as follows (contraindications; clinically significant; weak): SOF/VEL (1.4%; 8.1%; 0.9%), GLE/PIB (0.2%; 55.3%; 4.7%) and SOF/VEL/VOX (1.6%; 53.0%; 4.0%) (Figure 2a).

Inclusion of lipid-lowering drugs (particularly atorvastatin and simvastatin) in the analysis yielded the following percentages of potential DIs: 10.3% contraindications, 46.3% clinically significant and 3.2% weak. The percentages of DIs associated with each class of pDAAs were as follows (contraindications; clinically significant; weak): SOF/VEL (1.4%; 23.0%; 0.9%), GLE/PIB (12.8%; 60.8%; 4.7%) and SOF/VEL/VOX (16.6%; 55.1%; 4.9%) (Table 2 and Figure 2b).

The reasons for prescribing CV drugs were as follows: (i) enalapril (n = 365): arterial hypertension (n = 195, 53%), heart failure (n = 95, 26%) and renal failure (n = 75, 21%); (ii) atorvastatin (n = 85): secondary prevention (n = 52, 61%) and dyslipidemia (n = 33, 39%); (iii) amiodarone (n = 18): tachycardia (n = 8, 44%) and ventricular fibrillation (n = 10, 56%); and (iv) digoxin (n = 13): heart failure with atrial fibrillation (n = 13, 100%).

Atorvastatin was the drug with the highest potential for DIs (contraindicated: n = 85, 6.6%). During the administration of pDAAs, reasonable alternatives determined by physicians included the following: (i) discontinuation of atorvastatin (n = 14, 16.5%); (ii) dose reduction (n = 33, 38.8%); and (iii) substitution with another drug (n = 38, 44.7%).

**Discussion**

The present study showed that more than one third of patients with HCV infection received concomitant medications acting upon the CV system. Statins such as atorvastatin and simvastatin had increased risks of potential DIs. SOF/VEL had a lower risk of DIs than other pDAAs.

Patients with HCV infection tend to have many comorbidities. For example, Basseri found that kidney disease, diabetes and obesity were more prevalent in patients with HCV infection compared with the general population in the United States. McKibben concluded that HCV infection was associated with CV disease risk.

Notwithstanding its methodological limitations, the findings of our study agree with those reported in the literature. Some studies have found that two-thirds of patients experience potential interactions with DAAs, and that approximately 20% of concurrent drugs are contraindicated. The PITER study found that 30% to 44% of all patients receiving DAAs were at risk of clinically significant interactions. The authors underscored the need for greater care when these drugs are administered, particularly to patients with moderate to severe liver disease. Other studies reported similar or substantially higher percentages of DIs. Our results agree with those of previous studies, although we recorded a lower proportion of clinically relevant drug interactions. This may be because our study was conducted with the more recently marketed pDAAs. The literature available for comparison is relatively limited.
Table 2. Potential drug interactions of pangenotypic direct-acting antivirals (pDAAs).

| pDAA            | n  | CVS+LL (%) | CV drug  | Magnitude     |
|-----------------|----|------------|----------|---------------|
| SOF/VEL         | 18 | 1.4%       | Amiodarone | Contraindicated |
|                 | 85 | 6.6%       | Atorvastatin | Significant   |
|                 | 77 | 6.0%       | Simvastatin |
|                 | 38 | 3.0%       | Carvedilol |
|                 | 25 | 1.9%       | Diltiazem  |
|                 | 19 | 1.5%       | Rosuvastatin |
|                 | 13 | 1.0%       | Digoxin    |
|                 | 11 | 0.9%       | Pitavastatin |
|                 | 28 | 2.2%       | Others     |
|                 | 12 | 0.9%       | Colestyramine | Weak         |
| GLE/PIB         | 85 | 6.6%       | Atorvastatin | Contraindicated |
|                 | 77 | 6.0%       | Simvastatin |
|                 | 3  | 0.2%       | Dabigatran |
|                 | 365| 28.4%      | Enalapril  | Significant   |
|                 | 77 | 6.0%       | Acenocoumarol |
|                 | 73 | 5.7%       | Olmesartan |
|                 | 39 | 3.0%       | Irbesartan |
|                 | 38 | 3.0%       | Carvedilol |
|                 | 26 | 2.0%       | Telmisartan |
|                 | 25 | 1.9%       | Diltiazem  |
|                 | 19 | 1.5%       | Rosuvastatin |
|                 | 18 | 1.4%       | Amiodarone |
|                 | 15 | 1.2%       | Gemfibrozil |
|                 | 15 | 1.2%       | Pravastatin |
|                 | 13 | 1.0%       | Digoxin    |
|                 | 11 | 0.9%       | Ezetimibe  |
|                 | 11 | 0.9%       | Pitavastatin |
|                 | 37 | 2.9%       | Others     |
|                 | 49 | 3.8%       | Candesartan | Weak         |
|                 | 12 | 0.9%       | Colestyramine |
| SOF/VEL/VOX     | 85 | 6.6%       | Atorvastatin | Contraindicated |
|                 | 77 | 6.0%       | Simvastatin |
|                 | 19 | 1.5%       | Rosuvastatin |
|                 | 18 | 1.4%       | Amiodarone |
|                 | 11 | 0.9%       | Pitavastatin |
|                 | 3  | 0.2%       | Dabigatran |
|                 | 365| 28.4%      | Enalapril  | Significant   |
|                 | 73 | 5.7%       | Olmesartan |
|                 | 60 | 4.7%       | Valsartan  |
|                 | 49 | 3.8%       | Candesartan |
|                 | 38 | 3.0%       | Carvedilol |
|                 | 26 | 2.0%       | Telmisartan |
|                 | 25 | 1.9%       | Diltiazem  |
|                 | 15 | 1.2%       | Pravastatin |
|                 | 13 | 1.0%       | Digoxin    |

(continued)
We found that SOF/VEL exhibited a lower proportion of DIs compared with other regimens. SOF is a NS5B polymerase inhibitor, while VEL is an NS5 replication complex inhibitor. The intracellular metabolic activation of SOF is mediated by nucleotide phosphorylation and hydrolase activity (generally of low affinity and high

table 2. continued

| pDAA     | n  | CVS+LL (%) | CV drug | Magnitude |
|----------|----|------------|---------|-----------|
| 11       | 0.9% | Ezetimibe
| 33       | 2.6% | Others
| 39       | 3.0% | Irbesartan Weak
| 12       | 0.9% | Cholestyramine

Values reported as percentage of patients.
PDAAs, pan-genotypic direct-acting antivirals; CVS, cardiovascular system; SOF/VEL, sofosbuvir/velpatasvir; GLE/PIB, glecaprevir/pibrentasvir; SOF/VEL/VOX, sofosbuvir/velpatasvir/voxilaprevir; LL, lipid-lowering drugs.

Figure 2. Potential cardiovascular system drug interactions according to pan-genotypic direct-acting antiviral (pDAA) regimen. (a) Not including lipid-lowering agents and (b) Including lipid-lowering agents. Values reported as percentages of patients.
PDAAs, pan-genotypic direct-acting antivirals; SOF/VEL, sofosbuvir/velpatasvir; GLE/PIB, glecaprevir/pibrentasvir; SOF/VEL/VOX, sofosbuvir/velpatasvir/voxilaprevir.

We found that SOF/VEL exhibited a lower proportion of DIs compared with other regimens. SOF is a NS5B polymerase inhibitor, while VEL is an NS5 replication complex inhibitor. The intracellular metabolic activation of SOF is mediated by nucleotide phosphorylation and hydrolase activity (generally of low affinity and high

...
capacity), and is therefore unlikely to be affected by concomitant medications. Recent reviews reported that administration of drugs concomitantly with SOF generally resulted in fewer DIs than with protease inhibitor-based regimens. However, the analysis of each DI was theoretical, and further interaction studies would be required to confirm the real effect. Interactions may occur at the phases of drug absorption, distribution, or metabolism. The P450 enzyme system (CYP450), and particularly isoenzyme CYP3A4, is responsible for most drug oxidation. The administration of inducers, inhibitors or substrates of this enzyme system may alter the plasma concentrations of drugs, and thus the pharmacological response.

According to the indications for administration of some CV medications such as enalapril, atorvastatin, amiodarone and digoxin, it would be difficult to adopt a single strategy during the period of pDAA administration. For example, it is advisable to monitor blood pressure and heart rate and/or to reduce the dose of antihypertensive treatments. In the case of amiodarone, one should consider replacement with another drug or dose reduction in the face of DIs, and cardiac function should be monitored. In the case of statins, it is advisable to reduce the dose and monitor potential side effects because of the increased risk of myopathy and rhabdomyolysis. Nevertheless, the safest pDAA should be chosen based on the concomitant medications used in each patient. The results of our study regarding potential DIs with statins have also been reported in other published studies.

The present study had several limitations inherent to retrospective studies. These included underreporting of the disease and potential variability of professionals and patients, because an observational design was used. It should be noted that this study design is not free from biases, including those based on socioeconomic background, cultural or educational level, drug doses used, treatment duration, treatment adherence, or treatment suitability. In addition, over-the-counter drugs, patient self-medication or prescriptions issued at other health institutions (public or private) were not considered in our study. Our study could not account for over-the-counter drugs (not funded by the Spanish National Health System). However, we believe that this circumstance is rare. However, these factors may together have led to underestimation of DIs in our study. Our study demonstrated several potential DIs in patients with HCV. Other limitations of the study included bias in selection of the drug to be administered by the attending physician, as well as potentially limited external validity. Our results therefore should be interpreted with caution. Potential DIs are a serious problem in clinical practice, but many of them can be avoided by adjusting drug dosage or selecting a safer alternative drug. New care models, including e-prescription support tools or clinical decision support systems, may be of considerable help for clinicians in this respect. Early detection and treatment are important for prevention of the most severe consequences of HCV infection.

**Conclusions**

About one third of patients with HCV infection were concomitantly treated with CV drugs. Protease inhibitor pDAAs may have increased numbers of DIs with CV drugs. SOF/VEL may have fewer DIs than other pDAAs.

**Author contributions**

The study was conceived and designed by A. Sicras. Data compilation and statistical analysis was performed by A. Sicras. All authors participated in data interpretation and in manuscript writing, review, and approval.
Declaration of conflicting interest

A. Sicras was an independent consultant for the development of this manuscript. R. Morillo has no conflicts of interest.

Funding

This study was sponsored by Gilead Sciences.

ORCID iD

Antoni Sicras-Mainar https://orcid.org/0000-0002-8232-293X

References

1. Pineda JA, Climent B, García F, et al. Executive summary: Consensus document of GEHEP of the Spanish Society of Infectious Diseases and Clinical Microbiology (SEIMC), along with SOCIDROGALCOHOL, SEPD and SOMAPA on hepatitis C virus infection management in drug users. *Enferm Infecc Microbiol Clin* 2020; 38: 127–131.
2. European Association for the Study of the Liver. EASL recommendations on treatment of hepatitis C 2018. *J Hepatol* 2018; 69: 461–511.
3. Pérez AB, Chueca N, Macías J, et al. Prevalence of resistance associated substitutions and efficacy of baseline resistance-guided chronic hepatitis C treatment in Spain from the GEHEP-004 cohort. *PLoS One* 2019; 14: e0221231.
4. Han R, Zhou J, François C, et al. Prevalence of hepatitis C infection among the general population and high-risk groups in the EU/EEA: A systematic review update. *BMC Infect Dis* 2019; 19: 655.
5. Romero-López C and Berzal-Herranz A. The role of the RNA-RNA interactome in the hepatitis C virus life cycle. *Int J Mol Sci* 2020; 21: 1479.
6. Mohanty A, Salameh S and Butt AA. Impact of direct acting antiviral agent therapy upon extrahepatic manifestations of hepatitis C virus infection. *Curr HIV/AIDS Rep* 2019; 16: 389–394.
7. Misra S, Dieterich DT, Saberi B, et al. Direct-acting antiviral treatment of acute hepatitis C virus infections. *Expert Rev Anti Infect Ther* 2018; 16: 599–610.
8. Paolucci S, Novazzi F, Piralla A, et al. Viral dynamics among HCV infected patients with different genotypes treated with genotypic specific or pan-genotypic direct-acting antiviral agent combinations. *Infect Drug Resist* 2019; 12: 1975–1984.
9. Asselah T, Marcellin P and Schinazi RF. Treatment of hepatitis C virus infection with direct-acting antiviral agents: 100% cure? *Liver Int* 2018; 38: 7–13.
10. Keast SL, Holderread B, Cothran T, et al. Hepatitis C direct-acting antiviral treatment selection, treatment failure, and use of drug-drug interactions in a state Medicaid program. *J Manag Care Spec Pharm* 2019; 25: 1261–1267.
11. Talavera Pons S, Boyer A, Lamblin G, et al. Managing drug-drug interactions with new direct-acting antiviral agents in chronic hepatitis C. *Br J Clin Pharmacol* 2017; 83: 269–293.
12. Cohen E and Liapakis A. Pharmacokinetics and important drug-drug interactions to remember when treating advanced chronic kidney disease patients with hepatitis C direct acting anti-viral therapy. *Semin Dial* 2019; 32: 141–151.
13. Sicras Mainar A, Navarro Artieda R, Hernández I, et al. Prevalence of the potential drug-drug interactions between pangenotypic direct-acting antivirals and the concomitant medications associated with patients with chronic hepatitis C virus infection in Spain. *Gastroenterol Hepatol* 2019; 42: 465–475.
14. Sicras-Mainar A, Enríquez JL, Hernández I, et al. Validation and representativeness of the Spanish BIG-PAC database: integrated computerized medical records for research into epidemiology, medicines and health resource use (real world evidence). *Value Health* 2019; 22: S734.
15. Charlson ME, Pompei P, Ales KL, et al. A new method of classifying prognostic comorbidity in longitudinal studies: Development and validation. *J Chronic Dis* 1987; 40: 373–383.
16. World Health Organization. The Anatomical Therapeutic Chemical
10

Classification System with Defined Daily Doses (ATC/DDD). http://www.who.int/classifications/atcddd/en/ (2003, accessed 28 September 2020).

17. University of Liverpool. University of Liverpool HIV & Hepatitis Pharmacology Group Drug Interaction Charts. http://www.hep-druginteractions.org/Interactions.aspx (2020, accessed 28 September 2020).

18. Basseri B, Yamini D, Chee G, et al. Comorbidities associated with the increasing burden of hepatitis C infection. Liver Int 2010; 30: 1012–1018.

19. McKibben RA, Haberlen SA, Post WS, et al. A cross-sectional study of the association between chronic hepatitis C virus infection and subclinical coronary atherosclerosis among participants in the multicenter AIDS cohort study. J Infect Dis 2016; 213: 257–265.

20. Kondili LA, Gaeta GB, Ieluzzi D, et al. Real-life data on potential drug-drug interactions in patients with chronic hepatitis C viral infection undergoing antiviral therapy with interferon-free DAAs in the PITER Cohort Study. PLoS One 2017; 12: e0172159.

21. Kawabe N, Hashimoto S and Yoshioka K. Editorial: Comorbidities, concomitant medications, and potential drug-drug interactions with interferon-free direct-acting anti-viral agents in chronic hepatitis C. Aliment Pharmacol Ther 2019; 49: 116–117.

22. Roncero C, Villegas JL, Martínez-Rebollar M, et al. The pharmacological interactions between direct-acting antivirals for the treatment of chronic hepatitis C and psychotropic drugs. Expert Rev Clin Pharmacol 2018; 11: 999–1030.

23. Dick TB, Lindberg LS, Ramírez DD, et al. A clinician’s guide to drug-drug interactions with direct-acting antiviral agents for the treatment of hepatitis C viral infection. Hepatol 2016; 63: 634–643.

24. Crouchet E, Baumert TF and Schuster C. Hepatitis C virus apolipoprotein interactions: Molecular mechanisms and clinical impact. Expert Rev Proteomics 2017; 14: 593–606.

25. Casas Arrate J, Lázaro López A and De Miguel Cascoén M. Interacciones farmacológicas. El Farmacéutico Hospitales 2017; 209: 33–38.

26. Schulte B, Wübbolding M, Marra F, et al. Frequency of potential drug-drug interactions in the changing field of HCV therapy. Open Forum Infect Dis 2020; 7: ofaa040.